

# Index

## A

A870 allele, 101  
Alternative splicing, 100  
Androgen receptor (AR), 68, 103  
Antiproliferative TGF- $\beta$  pathway, 31  
Autophagy, 114, 115

## B

Beclin-1, 117  
*Beclin-1/Atg6*, 118  
Biochemical analysis, 138  
BRCA1, 78

## C

CAAT enhance-binding protein (C/EBP $\beta$ ), 64  
Carbohydrate response element-binding protein (ChREBP), 70  
Carboxyl terminal domain (CTD), 71  
CDK4/CDK6, 113, 125  
Cdk4-/Cdk6-specific inhibitors, 141  
CDK-activating kinase (CAK), 12, 143  
Cell cycle entry and exit, 10  
Cell cycle genes homology region (CHR), 80  
Cell cycle-independent functions, 41, 42  
Cell cycle progression, 134  
Cell cycle regulators, 91  
Central nervous system (CNS), 40  
Chromosomal instability (CIN), 73  
Chromosomal translocations and gene amplification, 93  
Cip/Kip family, 11  
Colony-stimulating factor-1 (CSF-1), 4  
Core cell cycle machinery, 2–4

Cre-loxP system, 38  
Cyclin activating kinase (CAK), 71  
Cyclin-cyclin-dependent kinase (cyclin-Cdk), 62  
Cyclin D- and CKD4/6-deficient mice vs. cancer  
    BCL/ABL-driven transformation, 45  
    breast cancer, 42  
    *CCND1* gene, 42  
    luminal and mammary epithelial cells, 43  
    mitogenic signaling pathways/aberrant proteolytic degradation, 43  
    MMTV-driven expression, 43  
    Neu-driven signal transduction pathway, 44  
    p53 deficiency, 43  
    Ras and c-Myc, 45  
    thymomas, 45  
    Wnt-induced tumors, 44  
Cyclin D-CDK4/CDK6 complexes, 112  
Cyclin D inactivating pRb dogma, 139  
Cyclin D1, 93–94  
    AR activity, 103  
    biochemical/molecular analyses, 100  
    cancer, 98–100  
    *CCND1* dysregulation, 92  
    CDK4 complexes, 104  
    CDK4/6, 92, 105  
    and cyclin D1b, 102  
    D1/CDK4 kinase, 99  
    ERK1 activity, 96  
    ER $\alpha$  activity, 103  
    Fbxo4, 99  
    gene amplification, 92  
    growth factor, 93–94  
    metabolism, 122–125  
    mutants, 99

- Cyclin D1 (*cont.*)
- mutations, 99
  - nuclear and cytoplasmic compartments, 96
  - polymorphism (G/A870), 101
  - posttranslational control, 93
  - regulatory aspect, 95
  - Sam68 splicing factor, 101
  - splicing-derived isoforms, 103
  - T286A mutations, 102
  - titrating activity, 94
- Cyclin D1/CDK4 complexes, 93, 94
- Cyclin D1/CDK6 kinases, 92
- Cyclin D1a, 76
- Cyclin D1b, 76
- Cyclin D1-CDK-pRB-E2F deregulation, 125
- Cyclin D1 function, 93
- Cyclin D1 induction, 7
- Cyclin D1<sup>KE/KE</sup>* mammary epithelial cells, 114
- Cyclin D1<sup>KE/KE</sup>* mice, 114
- Cyclin-dependent kinases (CDKs), 112
- carcinogenesis, 28
  - cell cycle, 28, 30
  - CIP/KIP proteins, 30
  - D-type cyclins, 28
  - G1- and S-phase, 29
  - interphase/metaphase transition, 29
  - knock-out or knock-in mice, 28
  - meiotic maturation, 28
  - MPF, 29
  - multicellular organisms, 28
  - posttranslational modification, 30
  - regulatory cofactors (cyclins), 28
  - sea urchin and clam embryos, 29
  - unicellular organisms, 28
- D**
- D-interacting myb-like protein 1 (designated DMP1), 74
- DNA damage response (DDR), 78, 79
- D-type cyclins, 34–36, 92, 114
- cancer treatment, 19–20
  - Cdk inhibitors/pRb family members, 39–41
  - CDK4/CDK6, 6–10, 19
    - inhibitors, 20
    - synthesis, 9
  - CDK6, 9
  - CDK6 holoenzymes, 12
  - cells lacking, 17
  - chromosomal DNA synthesis, 2
  - Cip/Kip proteins, 11
  - cyclin D1, 15, 17
  - cyclin-dependent kinase controls, 2
  - Cyl1 protein, 4
  - discovery, 2
  - double and triple knock-out mice, 36–39
  - E2F transcription factors, 31
  - extracellular environment, 30
  - G1 phase regulation, 30
  - G1/S transition, 12
  - genetic screen, 18
  - hybridization, 4
  - kinase-dependent functions, 32
  - kinetics, 8–9
  - lineage-dependent functions, 13–17
  - mammalian cells, 4
  - MAPK canonical pathway, 30–31
  - metazoans, 3
  - myotubes, 31
  - oogenesis, 31
  - phenotypes, 14
  - PRAD1 nucleotide sequence, 5
  - pre- and post-implantation mammalian development, 31
  - proliferating skeletal myoblasts, 31
  - quadruple and quintuple knock-out cells, 39
  - RB pathway, 19
  - single knock-out mice
    - autophagy, 35
    - catalytic subunits, 35
    - Cdk4- and Cdk6-deficient mice, 36
    - female infertility, 36
    - genetic mouse model, 34
    - growth deficiency and neurological phenotypes, 35
    - hematopoietic stem cell function, 36
    - lobuloalveolar development, 35
    - mouse uterine epithelium, 35
    - neurological deficiencies, 36
    - ovarian granulosa cells, 35
    - peripheral B-lymphocytes and pancreatic  $\beta$ -cells, 35
    - pituitary lactotroph cells, 36
    - retinal cells and photoreceptor cell death, 34
    - retinal development/mammary gland function, 35
    - T and B cell and erythrocyte development, 35
    - T lymphocytes, 36
  - SMAD3, 31
  - spermatogenesis, 31
  - stratified squamous epithelia, 31
  - unicellular eukaryotes, 3
  - Wnt/ $\beta$ -catenin, 10
- Dynamic process, 116

**E**

E1-activating enzyme, 95  
 E2F target genes, 11  
 Embryogenesis, 39  
 Embryonic stem cells (ESCs), 30  
*ERBB2*-driven mammary tumors, 112  
 Estrogen receptor (ER), 44, 64  
 Estrogen receptor binding elements (ERE), 44  
 Estrogen response element (ERE), 70  
 Estrogen signaling, 75  
 Ewing's sarcoma, 103  
 Exonic/intronic sequences, 100

**F**

Fatty acid oxidation (FAO), 119  
 Fbx4 mutations, 99  
 Fbxo4, 98  
 Flag/hemagglutinin (HA), 42  
 Follicle-stimulating hormone (FSH), 35

**G**

G/A870 allele, 101  
 G<sub>1</sub> cell cycle progression, 136, 142–144  
 G<sub>1</sub> cell cycle regulation, 142  
 G1-S cell cycle transition, 112, 115–123  
 G1-S transition, 112  
 Gene amplification, 92  
 General control non-repressed protein 5 (GCN5), 68  
 Genome-wide binding studies, 73, 74  
 Golgi bodies, 104

**H**

Hematopoietic stem cells (HSCs), 38  
 Hereditary nonpolyposis colorectal cancer (HNPCC), 99  
 Histone acetyltransferase (HAT), 68  
 Human pRb structure, 135  
 Hyper-phosphorylated pRb, 134, 139–141, 144

**I**

Immunoprecipitated proteins, 140

**K**

*Knockin* mouse, 113

**L**

Lamina-associated domains (LADs), 80  
 Lipoprotein lipase (LPL), 70

**M**

Mammalian cyclin-CDK complexes, 3  
 Mammalian cyclins, 5–6  
 Mammary epithelium, 113  
 Mantle B cell lymphoma (MCL), 92  
 Maturation-promoting factor/M-phase-promoting factor (MPF), 28  
 Mechanistic target of rapamycin, 117  
 Metabolic reprogramming, 115, 118  
 Micro-RNAs (miRNAs), 77  
 Mini-chromosome maintenance-deficient 2 (MCM2), 78  
 Mitogen-dependent signaling pathways, 91  
 Mouse embryonic fibroblasts (MEFs), 16, 120  
 Myc/forkhead box M1 (FOXM1), 31

**N**

Nonobese diabetic (NOD) type 1 diabetes, 35  
 Non-small-cell lung cancer (NSCLC), 119  
 Nuclear export signals (NES), 97  
 Nuclear lamina (NL), 80  
 Nuclear respiratory factor 1 (NRF1), 66, 123

**O**

*Ommis cellula e cellula*, 28

**P**

P300/CBP-associated factor (P/CAF), 42, 68, 78  
 Palbociclib, 19, 20  
 Peripheral nervous system (PNS), 40  
 Peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ), 42, 64  
 Phosphates, 140  
 Phosphodegron, 13  
 Phospho-peptide analyses, 139  
 Phospho-peptide mapping, 95  
 Phosphorylation, 94–96, 140  
 Phytohemagglutinin (PHA), 9  
 Pocket protein, 112  
 pRb mono-phosphorylation, 143  
 PRL receptor (PRLR), 44  
 Progesterone receptor (PR), 44  
 Pro-survival functions, 117  
 Protein arginine methyltransferases (PRMTs), 72  
 Protein kinases, 96  
 Protein movement, 97

**R**

RAF-MEK-ERK signaling pathway, 11  
*Rana pipiens*, 28

- Ras-PI3K and AKT signaling pathways, 96  
 RB kinase activity, 7  
 RB phosphorylation, 6–10  
 Rb tumor suppressor  
   Cdk4/Cdk6, 140  
   Cdk sites, 140  
   cyclin D-Cdk4/Cdk6, 137, 138, 140  
   D-Cdk4/Cdk6, 141, 143  
   DNA, 142  
   E2Fs, 134, 142  
     repression activity, 141  
     transcription factors, 137  
 functions, 134  
 G<sub>1</sub> cell cycle progression, 136  
 isoforms, 141  
 oncogenic pathway, 135  
 p16<sup>INK4a</sup> and p27<sup>Kip1</sup>, 136  
 phospho-peptide analyses, 139  
 phosphorylation, 140  
 prototypical cellular, 134  
 SDS-PAGE, 139  
 serum deprivation, 138  
 serum-restimulated cells, 137  
 Replication factor C (RFC), 41  
 Repression domain, 69  
 Retinoblastoma, 135  
 Retinoblastoma protein, 6, 64  
 RUNX family, 112
- S**  
 Sam68, 101  
 SCFFbx4- $\alpha$ Bcrystallin E3 ligase, 98  
 Senescence, 114  
 Senescence-associated secretory phenotype (SASP), 121  
 Senescence balance, 121–122  
 Single cyclin D elimination, 15  
 Small interfering RNA (siRNA), 75  
 Subgranular zone (SGZ), 34  
 Syndapins, 80
- T**  
 Tetraploid complementation technique, 40  
 Threonine 286, 95  
 Thyroid hormone receptor (TR), 64  
 T-loop threonine residue, 12  
 Transcription factor (TF)  
   A870G polymorphism, 76  
   basal transcription apparatus, 71  
   C/EBP $\beta$ , 75  
   characterization, 62  
   chromatin, 70, 71  
   coactivator proteins, 68–70  
   cultured cells, 64–66  
   cyclin D1, 72  
   cyclins D2 and D3, 67, 68  
   DMP1, 74, 75  
   DNA repair, 78, 79  
   D-type cyclins, 63, 64, 68–70  
   ER $\alpha$  signaling, 75  
   estradiol, 76  
   fat metabolism, 66, 67, 74  
   fibroblasts, 80  
   histone acetylation, 71  
   histone methylases, 72, 73  
   LADs, 80  
   LNCaP and tumorigenicity, 76  
   noncoding genome, 77  
   PACSIN, 80  
   PPARE, 72  
   subcellular localization, 62  
   subnuclear compartments and functions, 80  
 Transcriptional activation unit 1 (TAU1), 68  
 Transmembrane protease, serine 2 (TMPRSS2), 71  
 Tricarboxylic acid (TCA) cycle, 119  
 Tumorigenesis, 113
- U**  
 Ubiquitin proteasome system (UPS), 95  
 Unicellular eukaryotes, 3  
 Un-phosphorylated pRb, 134, 137, 140, 142–144
- V**  
 Vitamin D receptor (VDR), 68  
 Voltage-dependent anion channel (VDAC), 123